These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

776 related items for PubMed ID: 33252070

  • 1. White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
    van Waalwijk van Doorn LJC, Ghafoorian M, van Leijsen EMC, Claassen JAHR, Arighi A, Bozzali M, Cannas J, Cavedo E, Eusebi P, Farotti L, Fenoglio C, Fortea J, Frisoni GB, Galimberti D, Greco V, Herukka SK, Liu Y, Lleó A, de Mendonça A, Nobili FM, Parnetti L, Picco A, Pikkarainen M, Salvadori N, Scarpini E, Soininen H, Tarducci R, Urbani A, Vilaplana E, Meulenbroek O, Platel B, Verbeek MM, Kuiperij HB.
    J Alzheimers Dis; 2021; 79(1):163-175. PubMed ID: 33252070
    [Abstract] [Full Text] [Related]

  • 2. Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes.
    van Waalwijk van Doorn LJ, Gispert JD, Kuiperij HB, Claassen JA, Arighi A, Baldeiras I, Blennow K, Bozzali M, Castelo-Branco M, Cavedo E, Emek-Savaş DD, Eren E, Eusebi P, Farotti L, Fenoglio C, Ormaechea JF, Freund-Levi Y, Frisoni GB, Galimberti D, Genc S, Greco V, Hampel H, Herukka SK, Liu Y, Lladó A, Lleó A, Nobili FM, Oguz KK, Parnetti L, Pereira J, Picco A, Pikkarainen M, de Oliveira CR, Saka E, Salvadori N, Sanchez-Valle R, Santana I, Scarpini E, Scheltens P, Soininen H, Tarducci R, Teunissen C, Tsolaki M, Urbani A, Vilaplana E, Visser PJ, Wallin AK, Yener G, Molinuevo JL, Meulenbroek O, Verbeek MM.
    J Alzheimers Dis; 2017; 56(2):543-555. PubMed ID: 28059783
    [Abstract] [Full Text] [Related]

  • 3. CSF amyloid is a consistent predictor of white matter hyperintensities across the disease course from aging to Alzheimer's disease.
    Walsh P, Sudre CH, Fiford CM, Ryan NS, Lashley T, Frost C, Barnes J, ADNI Investigators.
    Neurobiol Aging; 2020 Jul; 91():5-14. PubMed ID: 32305782
    [Abstract] [Full Text] [Related]

  • 4. White matter hyperintensities and CSF Alzheimer disease biomarkers in preclinical Alzheimer disease.
    Soldan A, Pettigrew C, Zhu Y, Wang MC, Moghekar A, Gottesman RF, Singh B, Martinez O, Fletcher E, DeCarli C, Albert M, BIOCARD Research Team.
    Neurology; 2020 Mar 03; 94(9):e950-e960. PubMed ID: 31888969
    [Abstract] [Full Text] [Related]

  • 5. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
    Li X, Li TQ, Andreasen N, Wiberg MK, Westman E, Wahlund LO.
    J Intern Med; 2014 Apr 03; 275(4):418-27. PubMed ID: 24237038
    [Abstract] [Full Text] [Related]

  • 6. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment.
    Baldeiras I, Santana I, Leitão MJ, Gens H, Pascoal R, Tábuas-Pereira M, Beato-Coelho J, Duro D, Almeida MR, Oliveira CR.
    Alzheimers Res Ther; 2018 Mar 20; 10(1):33. PubMed ID: 29558986
    [Abstract] [Full Text] [Related]

  • 7. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
    Haris M, Yadav SK, Rizwan A, Singh A, Cai K, Kaura D, Wang E, Davatzikos C, Trojanowski JQ, Melhem ER, Marincola FM, Borthakur A.
    Neuroimage Clin; 2015 Mar 20; 7():598-604. PubMed ID: 25844314
    [Abstract] [Full Text] [Related]

  • 8. Regional White Matter Hyperintensities and Alzheimer's Disease Biomarkers Among Older Adults with Normal Cognition and Mild Cognitive Impairment.
    Newton P, Tchounguen J, Pettigrew C, Lim C, Lin Z, Lu H, Moghekar A, Albert M, Soldan A, BIOCARD Research Team.
    J Alzheimers Dis; 2023 Mar 20; 92(1):323-339. PubMed ID: 36744337
    [Abstract] [Full Text] [Related]

  • 9. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD.
    J Alzheimers Dis; 2015 Mar 20; 44(2):525-39. PubMed ID: 25391385
    [Abstract] [Full Text] [Related]

  • 10. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J, Verhülsdonk S, Pessanha F, Menge T, Seitz RJ, Kujovic M, Höft B, Supprian T, Lange-Asschenfeldt C.
    J Alzheimers Dis; 2019 Mar 20; 72(4):1119-1127. PubMed ID: 31683478
    [Abstract] [Full Text] [Related]

  • 11. White matter hyperintensities are associated with disproportionate progressive hippocampal atrophy.
    Fiford CM, Manning EN, Bartlett JW, Cash DM, Malone IB, Ridgway GR, Lehmann M, Leung KK, Sudre CH, Ourselin S, Biessels GJ, Carmichael OT, Fox NC, Cardoso MJ, Barnes J, Alzheimer's Disease Neuroimaging Initiative.
    Hippocampus; 2017 Mar 20; 27(3):249-262. PubMed ID: 27933676
    [Abstract] [Full Text] [Related]

  • 12. Heterogeneity of Cerebrospinal Fluid Biomarkers Profiles in Individuals with Distinct Levels of Cognitive Decline: A Cross-Sectional Study.
    Pais M, Loureiro J, do Vale V, Radanovic M, Talib L, Stella F, Forlenza O.
    J Alzheimers Dis; 2021 Mar 20; 81(3):949-962. PubMed ID: 33843685
    [Abstract] [Full Text] [Related]

  • 13. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O, Alzheimer’s Disease Neuroimaging Initiative.
    JAMA Psychiatry; 2014 Oct 20; 71(10):1183-91. PubMed ID: 25162367
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O.
    Arch Gen Psychiatry; 2012 Jan 20; 69(1):98-106. PubMed ID: 22213792
    [Abstract] [Full Text] [Related]

  • 18. Association between CSF Aβ42 and amyloid negativity in patients with different stage mild cognitive impairment.
    He B, Wang L, Xu B, Zhang Y, Alzheimer’s Disease Neuroimaging Initiative.
    Neurosci Lett; 2021 May 29; 754():135765. PubMed ID: 33667602
    [Abstract] [Full Text] [Related]

  • 19. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV, Aprahamian I, Radanovic M, Talib LL, Camargo MZ, Stella F, Machado-Vieira R, Gattaz WF.
    Bipolar Disord; 2016 Feb 29; 18(1):63-70. PubMed ID: 26876913
    [Abstract] [Full Text] [Related]

  • 20. Vascular and Alzheimer's disease markers independently predict brain atrophy rate in Alzheimer's Disease Neuroimaging Initiative controls.
    Barnes J, Carmichael OT, Leung KK, Schwarz C, Ridgway GR, Bartlett JW, Malone IB, Schott JM, Rossor MN, Biessels GJ, DeCarli C, Fox NC, Alzheimer's Disease Neuroimaging Initiative.
    Neurobiol Aging; 2013 Aug 29; 34(8):1996-2002. PubMed ID: 23522844
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.